Research further shows a significant association between patients with psoriasis and an increased incidence of obstructive sleep apnea (OSA).
The relationship between psoriasis and obstructive sleep apnea (OSA) was highlighted in a recent study published in the Archives of Dermatological Research.1 The retrospective cohort study, which represents one of the largest retrospective cohort analyses to examine this link, aimed to further explore whether individuals diagnosed with psoriasis are at higher risk of developing OSA.
The study used the TriNetX dataset, which includes electronic health records (EHR) from more than 96 million people across the United States. The research included 372,609 patients with psoriasis, matched against a control group of similar size based on age, sex, race, and OSA risk factors such as obesity, smoking, hypertension, diabetes, and hyperlipidemia.
The findings were clear: “Individuals with psoriasis were more likely to have a diagnosis of OSA compared to those without psoriasis," (RR, 1.26; 95% CI, 1.25–1.28; P < .0001), the researchers noted. Even after adjusting for known risk factors of OSA, the association remained statistically significant, with a risk ratio of 1.20 (95% CI, 1.18–1.21; P < .0001), showing that people with psoriasis had a 20% higher chance of being diagnosed with OSA than their non-psoriasis counterparts.
The study's authors suggest that the link between psoriasis and OSA may not be coincidental, noting that “the bidirectional relationship between OSA and psoriasis suggests a common pathogenetic pathway.” They add that “previous studies found significant, positive, and even bidirectional association between OSA/psoriasis occurrence.”
The researchers emphasize that "The outcomes of our study build on trends seen in prior studies," including a 2016 Danish nationwide cohort study, which reported that 60,175 patients with mild or severe psoriasis had a 1.36 to 1.53-fold increased likelihood of developing OSA.2 Another analysis involving 5,140 psoriasis patients in the All of Us Research Program reported a 1.45-fold increase in the odds of OSA among people with psoriasis, even after adjusting for common risk factors.3
This new study significantly expands on these earlier findings by using a much larger sample size, improving the generalizability of the results and “warranting further investigation into shared pathophysiology,” the authors note.
Psoriasis is also strongly associated with cardiovascular disorders, which are prevalent in patients with OSA. Biologic treatments often used for psoriasis have also been shown to improve cardiovascular morbidity.4 “Therefore, futureresearch considering psoriasis severityand systemic/biologic treatments can significantly enhance understanding ofthis relationship,” the researchers suggest.1
However, the study did acknowledge certain limitations, particularly the reliance on EHR data, which could introduce misclassification bias. Additionally, the severity of psoriasis or OSA in individual patients was not documented, meaning that the results could be further refined in future studies that include more detailed clinical data.
Despite these limitations, the authors believe that the findings warrant further attention from healthcare providers. "With enhanced understanding, there may be a future role for formally assessing patients with psoriasis for OSA," with the authors suggesting a good starting point is for clinicians to consider incorporating sleep quality screenings in routine care for psoriasis patients.
The study’s findings highlight the significant public health implications of the association between psoriasis and obstructive sleep apnea (OSA), given that OSA affects up to 20% of American adults. Due to the serious complications associated with untreated OSA, such as cardiovascular disease, mental health disorders, and increased daytime fatigue, early detection and management in psoriasis patients could have significant long-term benefits.5
References
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
Rozanolixizumab Effective in Patients with MuSK MG, Analysis Shows
October 23rd 2024A new subgroup analysis of patients with muscle-specific tyrosine kinase (MuSK) autoantibody-positive (Ab+) myasthenia gravis (MG) shows rozanolixizumab (Rystiggo) contributes to meaningful symptom improvement.
Read More
Frameworks for Advancing Health Equity: Community Wellness Centers
September 27th 2024Delia Orosco, MS, director of Community Wellness Centers at Inland Empire Health Plan, shares insight into innovative initiatives provided by the wellness centers and their new mobile mammogram clinics.
Listen